Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge

References

• Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002; 87(3): 978–982.
   PubMed Web of Science ®Google Scholar
• Wexler DJ, Nathan DM, Grant RW, Regan S, Van Leuvan AL, Cagliero E. Prevalence of elevated hemoglobin A1c among patients admitted to the hospital without a diagnosis of diabetes. J Clin Endocrinol Metab. 2008; 93(11): 4238–4244.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008; 31(3): 596–615.
   PubMed Web of Science ®Google Scholar
• Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol. 2005; 96(3): 363–365.
   PubMedGoogle Scholar
• Mechanick JI. Metabolic mechanisms of stress hyperglycemia. JPEN J Parenter Enteral Nutr. 2006; 30(2): 157–163.
   PubMedGoogle Scholar
• Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006; 12(4): 358–362.
   PubMedGoogle Scholar
• Silverman RA, Pahk R, Carbone M, et al. The relationship of plasma glucose and HbA1c levels among emergency department patients with no prior history of diabetes mellitus. Acad Emerg Med. 2006; 13(7): 722–726.
   PubMed Web of Science ®Google Scholar
• Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003; 78(12): 1471–1478.
   PubMed Web of Science ®Google Scholar
• Gornik I, Gomik O, Gasparovié V. HbA1c is outcome predictor in diabetic patients with sepsis. Diabetes Res Clin Pract. 2007; 77(1): 120–125.
   PubMedGoogle Scholar
• Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr. 1998; 22(2): 77–81.
   PubMed Web of Science ®Google Scholar
• Norhammar AM, Rydén L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 1999; 22(11): 1827–1831.
   PubMed Web of Science ®Google Scholar
• Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001; 79(2–3): 207–214.
   PubMedGoogle Scholar
• Gustafsson I, Kistorp CN, James MK, Faber JO, Dickstein K, Hildebrandt PR; OPTIMAAL Study Group. Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. Am Heart J. 2007; 154(3): 470–476.
   PubMedGoogle Scholar
• Halkos ME, Lattouf OM, Puskas JD, et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg. 2008; 86(5): 1431–1437.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Wilding GE, Dhindsa G, et al. Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure. Endocr Pract. 2004; 10(6): 467–471.
   PubMedGoogle Scholar
• Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ. 1997; 314(7090): 1303–1306.
   PubMedGoogle Scholar
• Williams LS, Rotich J, Qi R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002; 59(1): 67–71.
   PubMedGoogle Scholar
• Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000; 102(10): 1193–1209.
   PubMed Web of Science ®Google Scholar
• Malmberg K, Rydén L, Hamsten A, Herlitz J, Waldenström A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J. 1996; 17(9): 1337–1344.
   PubMedGoogle Scholar
• Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999; 99(20): 2626–2632.
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19): 1359–1367.
   PubMed Web of Science ®Google Scholar
• Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004; 114(9): 1187–1195.
   PubMed Web of Science ®Google Scholar
• Vanhorebeek I, Langouche L, Van den Berghe G. Intensive insulin therapy in the intensive care unit: update on clinical impact and mechanisms of action. Endocr Pract. 2006; 12(suppl 3): 14–22.
   PubMedGoogle Scholar
• Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet. 2009; 373(9663): 547–556.
   PubMed Web of Science ®Google Scholar
• Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008; 358(2): 125–139.
   PubMed Web of Science ®Google Scholar
• NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009; 360(13): 1283–1297.
   PubMed Web of Science ®Google Scholar
• Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009; 180(8): 821–827.
   PubMed Web of Science ®Google Scholar
• Devos P, Preiser JC, Mélot C. GluControl Steering Committee. Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the GluControl study. Intensive Care Med. 2007; 33(suppl 2): S189.
   Google Scholar
• Kaukonen KM, Rantala M, Pettilä V, Hynninen M. Severe hypoglycemia during intensive insulin therapy. Acta Anaesthesiol Scand. 2009; 53(1): 61–65.
   PubMedGoogle Scholar
• Inzucchi SE, Siegel MD. Glucose control in the ICU—how tight is too tight? N Engl J Med. 2009; 360(13): 1346–1349.
   PubMedGoogle Scholar
• Van den Berghe G, Mesotten D, Vanhorebeek I. Intensive insulin therapy in the intensive care unit. CMAJ. 2009; 180(8): 799–800.
   PubMedGoogle Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329(14): 977–986.
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405–412.
   PubMed Web of Science ®Google Scholar
• Abourizk NN, Vora CK, Verma PK. Inpatient diabetology. The new frontier, J Gen Intern Med. 2004; 19(5 pt 1): 466–471.
   PubMedGoogle Scholar
• Gearhart JG, Duncan JL III, Replogle WH, Forbes RC, Walley EJ. Efficacy of sliding-scale insulin therapy: a comparison with prospective regimens. Fam Pract Res J. 1994; 14(4): 313–322.
   PubMedGoogle Scholar
• Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy. 2006; 26(10): 1421–1432.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? Am J Med. 2007; 120(7): 563–567.
   PubMed Web of Science ®Google Scholar
• Penfold S, Gouni R, Hamilton P, Richardson T, Kerr D. Immediate in-patient management of hyperglycaemia—confusion rather than consensus? QJM. 2008; 101(2): 87–90.
   PubMedGoogle Scholar
• Schnipper JL, Barsky EE, Shaykevich S, Fitzmaurice G, Pendergrass ML. Inpatient management of diabetes and hyperglycemia among general medicine patients at a large teaching hospital. J Hosp Med. 2006; 1(3): 145–150.
   PubMed Web of Science ®Google Scholar
• Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004; 27(2): 553–591.
   PubMed Web of Science ®Google Scholar
• ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006; 29(8): 1955–1962.
   PubMedGoogle Scholar
• Cook CB, Jameson KA, Hansell ZC, et al. Beliefs about hospital diabetes and perceived barriers to glucose management among inpatient midlevel practitioners. Diabetes Educ. 2008; 34(1): 75–83.
   PubMedGoogle Scholar
• Henry L, Dunning E, Halpin L, Stanger D, Martin L. Nurses' perceptions of glycemic control in patients who have undergone cardiac surgery. Clin Nurse Spec. 2008; 22(6): 271–277.
   PubMedGoogle Scholar
• Aragon D. Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care. 2006; 15(4): 370–377.
   PubMedGoogle Scholar
• Lansang CM, Umpierrez GE. Management of inpatient hyperglycemia in noncritically ill patients. Diabetes Spectrum. 2008; 21(4): 245–255.
   Google Scholar
• Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997; 278(20): 1663–1669.
   PubMed Web of Science ®Google Scholar
• Leslie CA, Satin-Rapaport W, Matheson D, Stone R, Enfield G. Psychological insulin resistance: a missed diagnosis? Diabetes Spectrum. 1994; 7(1): 52–57.
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32(1): 193–203.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993; 91(1): 301–307.
   PubMed Web of Science ®Google Scholar
• Gutniak M, Orskov C, Hoist JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med. 1992; 326(20): 1316–1322.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997; 273(5 pt 1): E981–E988.
   PubMed Web of Science ®Google Scholar
• Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997; 40(2): 205–211.
   PubMed Web of Science ®Google Scholar
• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Hoist JJ. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci. 1993; 38(4): 665–673.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003; 26(10): 2835–2841.
   PubMed Web of Science ®Google Scholar
• Meneilly GS, Veldhuis JD, Elahi D. Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(11): 6251–6256.
   PubMedGoogle Scholar
• Lerche S, Soendergaard L, Rungby J, et al. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf). 2009; 71(4): 500–506.
   PubMedGoogle Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87(3): 1239–1246.
   PubMed Web of Science ®Google Scholar
• Saha JK, Xia J, Engle SK, Chen YF, Glaesner W, Jakubowski JA. A model of controlled acute hyperglycemia in rats: effects of insulin and glucagon-like peptide-1 analog. J Pharmacol Exp Ther. 2006; 316(3): 1159–1164.
   PubMedGoogle Scholar
• Nauck MA, Walberg J, Vethacke A, et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004; 118(1–2): 89–97.
   PubMedGoogle Scholar
• Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care. 2009; 13(3): R67.
   PubMedGoogle Scholar
• Sourij H, Schmölzer I, Kettler-Schmut E, et al. Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes Care. 2009; 32(9): 1669–1671.
   PubMedGoogle Scholar
• Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vase Dis Res. 2004; 1 (1): 43.
   Google Scholar
• Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004; 287(6): E1209–E1215.
   PubMed Web of Science ®Google Scholar
• Vilsbell T, Agersø H, Lauritsen T, et al. The elimination rates of intact GIP as well as its primary metabolite, GIP 3–42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept. 2006; 137(3): 168–172.
   PubMedGoogle Scholar
• Vilsbøl T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of type 2 diabetes mellitus. Dan Med Bull. 2004; 51 (4): 364–370.
   PubMedGoogle Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548): 1696–1705.
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30(8): 1448–1460.
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11): 2628–2635.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008; 372(9645): 1240–1250.
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5): 1083–1091.
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 146(7): 477–485.
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683): 39–47.
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373(9662): 473–481.
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brändle M, et al; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3): 268–278.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met + SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009; 52(10): 2046–2055.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009; 32(7): 1224–1230.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63(1): 46–55.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP; Sitagliptin Study 014 Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007; 23(6): 1329–1339.
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49(11): 2564–2571.
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12): 2638–2643.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Ohes Metab. 2007; 9(5): 733–745.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9(2): 194–205.
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008; 24(2): 537–550.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study. Clin Ther. 2006; 28(10): 1556–1568.
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(10): 959–969.
   PubMed Web of Science ®Google Scholar
• Allen E, Hollander P, Li J, Chen R; The Life Study Group. Saxagliptin added to a thiazolidinedione improves glycaemic control in patients with inadequately controlled type 2 diabetes: systematic review and meta-analysis. Presented at: 44th European Association for the Study of Diabetes Annual Meeting; September 7–11, 2008; Rome, Italy.
   Google Scholar
• Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV 181–040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009; 63(9): 1395–1406.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32(9): 1649–1655.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008; 31 (12): 2315–2317.
   PubMed Web of Science ®Google Scholar
• Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Diabetes. 2008; 57(suppl 1): A143.
   Google Scholar
• Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Algoliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009; 11(2): 167–176.
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12): 2632–2637.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5): 1092–1100.
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992; 267(11): 7402–7405.
   PubMed Web of Science ®Google Scholar
• Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes. 2004; 53(9): 2397–2403.
   PubMed Web of Science ®Google Scholar
• Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(11): 5991–5997.
   PubMed Web of Science ®Google Scholar
• Byetta (exenatide) [package insert]. Indianapolis, IN: Eli Lilly & Co; 2003.
   Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008; 24(1): 275–286.
   PubMed Web of Science ®Google Scholar
• Kothare PA, Linnebjerg H, Skrivanek Z, et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007; 45(2): 114–120.
   PubMed Web of Science ®Google Scholar
• Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006; 46(10): 1179–1187.
   PubMed Web of Science ®Google Scholar
• Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005; 45(9): 1032–1037.
   PubMed Web of Science ®Google Scholar
• Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol. 2005; 45(5): 570–577.
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009; 25(4): 1019–1027.
   PubMed Web of Science ®Google Scholar
• Noel RA, Braun DK, Patterson R, Bloomgren G. Increased risk of acute pancreatitis observed in patients with type 2 diabetes. Pancreas. 2008; 37(4): 487. Abstract.
   Google Scholar
• Amylin Pharmaceuticals IELaC. New drug application for exenatide once weekly accepted for review by FDA [news release], http://www.amylin.com. Accessed September 14, 2009.
   Google Scholar
• Kim T, Taylor K, Wilhelm K, Trautmann M, Zhuang D, Porter L. Exenatide once weekly treatment elicits sustained glycemic control and weight loss over 2 years. Presented at: 69th Scientific Sessions of the American Diabetes Association; June 5–9, 2009; New Orleans, LA; 159-OR.
   Google Scholar
• Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43(9): 1664–1669.
   PubMed Web of Science ®Google Scholar
• Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45(2): 195–202.
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003; 52(7): 1786–1791.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Novo Nordisk's Victoza® (liraglutide) receives marketing authorisation in Europe (July 3, 2009). http://www.novonordisk.com/press/sea/sea.asp?sNewsTypeGUID=&1Month=&1Year=&sLanguageCode=&sSearchText=&sShowNewsItemGUID=fef45783-0017-45f7-8185-ad751bad7019&sShowLanguageCode=en-GB. Accessed October 1, 2009.
   Google Scholar
• Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. In: Program and Abstracts of the American Diabetes Association (ADA). Presented at: 69th Scientific Sessions; June 5, 2009; New Orleans, LA.
   Google Scholar
• Nauck M, Frid A, Hermansen K, et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1): 84–90.
   PubMed Web of Science ®Google Scholar
• Buse J, Sesti G, Schmidt WE, et al. Switching from twice-daily exenatide to once-daily liraglutide improves glycemic control in T2D on oral agents. Presented at: 69th Scientific Sessions of the American Diabetes Association; June 5–9, 2009; New Orleans, LA.
   Google Scholar
• Helleberg H, Malm-Eijefält M, Bjørnsdottir I, et al. Metabolism and excretion of [Pal-3H]-liraglutide in human healthy subjects. Presented at: 68th Scientific Sessions of the American Diabetes Association; June 6–10, 2008; San Francisco, CA.
   Google Scholar
• Jacobsen V, Hindsberger C, Robson R, Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17–21, 2007; Amsterdam, The Netherlands.
   Google Scholar
• Flint A, Nazzal K, Jagielski P, Segel S, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22–26, 2007; Chicago, IL.
   Google Scholar
• Victoza (liraglutide) [package insert]. Bagsværd, Denmark: Novo Nordisk A/S; 2009.
   Google Scholar
• Malm-Eijefält M, Ekblom M, Brandsted L, Vouis J, Lennernäs H, Zdravkovic M. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Presented at: 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 6–10, 2008; San Francisco, CA.
   Google Scholar
• Kapitza C, Flint A, Hindsberger C, Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 6–10, 2008; San Francisco, CA.
   Google Scholar
• Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2007.
   Google Scholar
• Medical News Today. New post-hoc analyses show Januvia^TM (sitagliptin) provided significant blood sugar lowering sustained over two years [press release], http://www.medicalnewstoday.com/articles/153410.php#. Accessed October 22, 2009.
   Google Scholar
• Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006; 28(1): 55–72.
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 2005; 78(6): 675–688.
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009; 49(4): 483–488.
   PubMedGoogle Scholar
• Mistry GC, Bergman AJ, Luo WL, et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol. 2007; 47(2): 159–164.
   PubMedGoogle Scholar
• Mistry GC, Bergman AJ, Zheng W, et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol. 2008; 66(1): 36–42.
   PubMed Web of Science ®Google Scholar
• Wright D. Multiple dose administration of MK-0431 (sitagliptin), an inhibitor of dipeptidyl peptidase-IV, does not meaningfully alter the plasma pharmacokinetics or pharmacodynamics of single doses of warfarin. Clin Pharmacol Ther. 2006; 79: P76.
   Google Scholar
• US Food and Drug Administration. Information for Healthcare Professionals—Acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). September 25, 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm183764.htm. Accessed October 21, 2009.
   Google Scholar
• Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009.
   Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(5): 376–386.
   PubMed Web of Science ®Google Scholar
• Patel C, Castaneda L, Frevert U, Li L, Kornhauser DM, Boulton DW. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Diabetes. 2008; 57(suppl 1): A160.
   Google Scholar
• Gallwitz B. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs. 2008; 11(12): 906–917.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceutical Company Limited. Takeda provides update on the investigational fixed-dose combination of alogliptin and Actos® (pioglitazone HCl) [news release], http://www.takeda.com. Accessed September 9, 2009.
   Google Scholar
• Pratley RE, Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud. 2008; 5(2): 73–94.
   PubMedGoogle Scholar
• Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008; 30(3): 513–527.
   PubMed Web of Science ®Google Scholar
• Covington P, Christopher R, Davenport M, et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008; 30(3): 499–512.
   PubMed Web of Science ®Google Scholar
• Karim A, Fleck P, Hetman L, et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Presented at: 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 6–10, 2008; San Francisco, CA.
   Google Scholar
• Novartis AG. Novartis Group 2008 Annual Report. http://faculty.fuqua.duke.edu/~willm/Classes/Pharma/Pharma2009/0ClassMaterials/c07_Generics/Cases&Readings/0Online/Novartis_Sandoz_2008.pdf. Accessed September 15, 2009.
   Google Scholar
• Plutzky J, Garber AJ, Falahati A, Toft AD, Poulter NR. The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. Presented at: European Society of Cardiology Congress 2009; August 29 to September 2, 2009; Barcelona, Spain.
   Google Scholar
• Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
   Google Scholar
• Actos [package insert]. Deerfield, IL: Takeda Pharmaceuticals America; 2008.
   Google Scholar
• Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care. 2008; 31(10): 1960–1965.
   PubMedGoogle Scholar
• Rosenfalck AM, Hendel H, Rasmussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab. 2002; 4(1): 19–28.
   PubMedGoogle Scholar
• U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995; 44(11): 1249–1258.
   PubMed Web of Science ®Google Scholar
• Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005; 330(2): 577–584.
   PubMed Web of Science ®Google Scholar
• Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS. 2003; 111(12): 1117–1124.
   PubMed Web of Science ®Google Scholar
• Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002; 283(4): E745–E752.
   PubMed Web of Science ®Google Scholar
• Sturis J, Gotfredsen CF, Rømer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003; 140(1): 123–132.
   PubMed Web of Science ®Google Scholar
• Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006; 55(6): 1695–1704.
   PubMed Web of Science ®Google Scholar